Clinical Trial Update: Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC. [Phase 2]

View source ↗

Summary

Phase 2 trial comparing tislelizumab plus lenvatinib and GEMOX versus tislelizumab plus GEMOX for conversion therapy in potentially resectable locally advanced …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gallbladder Cancer
• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• GEMOX (gemcitabine + oxaliplatin)
• Lenvatinib (lenvatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer | Phase 2 | Status: UNKNOWN